IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive ...

IceCure Medical (Nasdaq:ICCM) announced today that it received an intention to grant notice from the European Patent Office.

As the largest study of its kind, ICE3 provides crucial data that can support the shift towards the de-escalation of breast cancer care with cryoablation as a less invasive procedure, enabling the ...

(UT Southwestern Medical Center) Cryoablation has not been approved by the U.S. Food and Drug Administration for breast cancer treatment, although an advisory committee for the agency did recently ...

IceCure Medical Ltd. (NASDAQ: ICCM) watched its shares make marginal gains Friday. The Israeli-based developer of ...

Icecure Medical ( ) has issued an update. IceCure Medical has received an Intention to Grant Notice from the European Patent Office for its innovative cryogenic system connector t ...

(Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal ...

Tomkovich FDA Advisory Panel voted in favor of IceCure's ProSense® cryoablation benefit-risk profile in early-stage low risk breast cancer in Nov. 2025 FDA's marketing authorization decision ...

IceCure Medical CEO Eyal Shamir said: "This is a significant milestone on the path towards the marketing authorisation of ProSense cryoablation in the US for early-stage low-risk breast cancer and ...

About IceCure Medical IceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the treatment of tumors (benign and cancerous) by freezing ...